Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T15:43:06.198Z.
Calculation as of: 2026-10-06T15:43:06.198Z.
Quote observation: 2026-10-06T15:40:24.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: be51af8dbdcf828107064bcf61af75d59853c311cbc38d104ed49a07c9c6f929
PE RATIO
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ORIC Pharmaceuticals, Inc. (ORIC) | $1.25B | N/A | N/A | N/A | N/A |
| Kardigan, Inc. (KARD)vs › | $1.28B | N/A | N/A | N/A | N/A |
| Cronos Group Inc. (CRON)vs › | $1.23B | 18.11 | 29.62 | 28.16 | 28.16 |
| MannKind Corporation (MNKD)vs › | $1.22B | N/A | 65.92 | 100.90 | 100.90 |
| Omada Health (OMDA)vs › | $1.22B | 326.19 | 351.15 | 351.15 | 351.15 |
| Innovage Holding Corp. (INNV)vs › | $1.22B | N/A | 92.39 | 92.39 | 92.39 |
| Alpha Tau Medical Ltd (DRTS)vs › | $1.32B | N/A | N/A | N/A | N/A |
| Damora Therapeutics, Inc. (DMRA)vs › | $1.17B | N/A | N/A | N/A | N/A |
| Nektar Therapeutics (NKTR)vs › | $1.16B | N/A | 10.01 | 10.01 | 83.50 |
| Avalyn Pharma Inc. Common Stock (AVLN)vs › | $1.15B | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$12.12
Forward EPS (Est.)
$-1.50
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
